Duo-Travatan

Decrease of IOP in patient w/ open-angle glaucoma or ocular HTN who are insufficiently responsive to topical β-blockers or prostaglandin analogues.

Adult including the elderly 1 drop in the conjunctival sac of the affected eye(s) once daily, in the morning or evening.

Bronchial asthma, a history of bronchial asthma or severe COPD. Sinus bradycardia, 2nd or 3rd degree AV block, overt cardiac failure or cardiogenic shock. Severe allergic rhinitis & bronchial hyperreactivity; corneal dystrophies; hypersensitivity to other β-blockers. Pregnancy or women who may become pregnant.

Oral Ca channel blockers, guanethidine, antiarrhythmics, digitalis glycosides, parasympathomimetics. Sudden w/drawal of clonidine. β-blockers, β-adrenergic blocking agents, other prostaglandins, antidiabetic agent.

The most common ocular adverse event observed in controlled clinical studies with TRAVATAN® 0.004% was ocular hyperemia which was reported in 35 to 50% of patients. Approximately 3% of patients discontinued therapy due to conjunctival hyperemia.

Ocular adverse events reported at an incidence of 5 to 10% included decreased visual acuity, eye discomfort, foreign body sensation, pain, and pruritus.

Ocular adverse events reported at an incidence of 1 to 4% included abnormal vision, blepharitis, blurred vision, cataract, cells, conjunctivitis, dry eye, eye disorder, flare, iris discoloration, keratitis, lid margin crusting, photophobia, subconjunctival hemorrhage, and tearing.

Nonocular adverse events reported at a rate of 1 to 5% were accidental injury, angina pectoris, anxiety, arthritis, back pain, bradycardia, bronchitis, chest pain, cold syndrome, depression, dyspepsia, gastrointestinal disorder, headache, hypercholesterolemia, hypertension, hypotension, infection, pain, prostate disorder, sinusitis, urinary incontinence, and urinary tract infection.